Online citations, reference lists, and bibliographies.
← Back to Search

Anticoagulation Decisions In Elderly Patients With Stroke.

S. Deltour, É. Pautas
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Primary and secondary prevention of stroke is often a challenge in elderly patients due to the increase in both thrombotic and hemorrhagic risks with age. In some cases, there is sufficient data in the elderly population to allow recommendations or anticoagulation decisions to be made, such as for the indication of anticoagulation to prevent stroke related to atrial fibrillation (AF) or the choice of oral anticoagulant therapy in this situation. In other situations, the less robust data leave some questions; this is the case for the delay to initiate an oral anticoagulant therapy after an AF-related ischemic stroke, for the management of antithrombotic treatment after a stroke of undetermined cause or after intracranial bleeding or in a high-risk bleeding situation associated with stroke in the elderly subject. These issues will be discussed in this paper.
This paper references
10.1161/01.STR.27.10.1765
Acute stroke with atrial fibrillation. The Copenhagen Stroke Study.
H. Jørgensen (1996)
10.1016/S0140-6736(97)04011-7
The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke
P. Sandercock (1997)
10.1016/S0140-6736(97)04011-7
The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke
C. Watkins (1997)
10.1001/ARCHINTE.159.7.677
Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls.
M. Man-Son-Hing (1999)
10.1161/01.STR.0000018081.33541.E3
Use of Intravenous Heparin by North American Neurologists: Do the Data Matter?
A. Al-Sadat (2002)
10.1161/01.STR.0000047036.77466.E8
Resolved: Heparin may be useful in selected patients with brain ischemia.
L. Caplan (2003)
10.1001/JAMA.296.24.2939
Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years.
R. Carandang (2006)
10.1093/EURHEARTJ/EHI825
Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study.
J. Heeringa (2006)
10.1161/01.STR.0000254600.92975.1f
Efficacy and Safety of Anticoagulant Treatment in Acute Cardioembolic Stroke: A Meta-Analysis of Randomized Controlled Trials
M. Paciaroni (2007)
10.1161/STROKEAHA.107.511402
Stroke Outcome in Those Over 80: A Multicenter Cohort Study Across Canada
G. Saposnik (2008)
10.1161/CIRCULATIONAHA.106.179918
Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
W. Rosamond (2008)
10.1056/NEJMoa0905561
Dabigatran versus warfarin in patients with atrial fibrillation.
S. Connolly (2009)
10.1016/S0140-6736(09)61343-X
Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial
D. Holmes (2009)
10.1378/chest.10-0134
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
R. Pisters (2010)
10.1161/STR.0b013e3181ec611b
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
L. Morgenstern (2010)
10.1111/j.1538-7836.2010.03882.x
Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk
G. Hawryluk (2010)
10.1161/STROKEAHA.110.593087
Optimal Timing of Resumption of Warfarin After Intracranial Hemorrhage
A. Majeed (2010)
10.1056/NEJMoa1107039
Apixaban versus warfarin in patients with atrial fibrillation.
C. Granger (2011)
10.1056/NEJMoa1009638
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
Manesh R Patel (2011)
10.1016/j.amjmed.2012.01.033
Risk of falls and major bleeds in patients on oral anticoagulation therapy.
J. Donzé (2012)
10.1016/S1474-4422(13)70079-6
Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials
W. Whiteley (2013)
10.1016/j.acvd.2013.04.001
Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people.
O. Hanon (2013)
10.1161/STR.0b013e318284056a
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
E. Jauch (2013)
10.1161/STROKEAHA.113.675140
Adelaide Stroke Incidence Study: Declining Stroke Rates but Many Preventable Cardioembolic Strokes
J. Leyden (2013)
10.1161/STR.0000000000000024
Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
W. Kernan (2014)
10.1016/S0140-6736(13)62343-0
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
C. Ruff (2014)
10.1016/j.jacc.2014.04.029
Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.
D. Holmes (2014)
10.1111/ijs.12309
European Stroke Organisation (ESO) Guidelines for the Management of Spontaneous Intracerebral Hemorrhage
T. Steiner (2014)
10.1001/jama.2014.15192
Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.
V. Reddy (2014)
10.1001/jama.2015.10082
Association Between Blood Pressure Control and Risk of Recurrent Intracerebral Hemorrhage.
A. Biffi (2015)
10.1161/CIRCULATIONAHA.115.015735
Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study
P. Nielsen (2015)
10.1016/j.ijcard.2015.03.334
Health status, geriatric syndromes and prescription of oral anticoagulant therapy in elderly medical in-patients with atrial fibrillation: a prospective observational study.
M. Bo (2015)
10.1093/eurheartj/ehv304
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis.
F. Andreotti (2015)
10.1001/jama.2015.0846
Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage.
J. Kuramatsu (2015)
10.1161/CIR.0000000000000152
Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association
D. Mozaffarian (2015)
10.1161/STR.0000000000000069
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
J. Hemphill (2015)
10.1161/STROKEAHA.115.012338
Effect of Anticoagulation on Hospitalization Costs After Intracranial Hemorrhage in Atrial Fibrillation: A Registry Study
A. S. Vestergaard (2016)
10.1093/eurheartj/ehw210
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
P. Kirchhof (2016)
10.1093/eurheartj/ehw054
The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation
Z. Hijazi (2016)
10.1161/STROKEAHA.116.012945
Use of Antithrombotic Therapy and Long-Term Clinical Outcome Among Patients Surviving Intracerebral Hemorrhage
Tobias Pilgaard Ottosen (2016)
10.1016/j.hrthm.2016.05.016
Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage.
Young-Ah Park (2016)
10.1016/j.jacc.2016.09.939
Reply: Ectopic Fat Deposition and Diabetes Mellitus.
E. Levelt (2016)
10.1016/j.amjmed.2016.05.041
Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
M. Barra (2016)
10.1016/j.jacc.2016.09.966
Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.
B. Steinberg (2016)
10.1056/NEJMra1510059
Pragmatic Trials.
I. Ford (2016)
10.1161/JAHA.117.005657
Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub‐Analysis From the PREFER in AF (PREvention oF Thromboembolic Events–European Registry in Atrial Fibrillation)
G. Patti (2017)
10.1161/STROKEAHA.116.014643
Optimal Timing of Anticoagulant Treatment After Intracerebral Hemorrhage in Patients With Atrial Fibrillation
Johanna Pennlert (2017)
10.1161/STROKEAHA.116.016327
Restarting Anticoagulant Therapy After Intracranial Hemorrhage: A Systematic Review and Meta-Analysis
S. Murthy (2017)
10.1111/bcp.13299
Trends in the prescription of novel oral anticoagulants in UK primary care
Simone Y Loo (2017)
10.1177/1747493016681019
Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design
T. Geisler (2017)
10.1016/j.thromres.2017.11.001
Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis.
C. Chai-Adisaksopha (2017)
10.1002/ana.25079
Oral Anticoagulation and Functional Outcome after Intracerebral Hemorrhage
A. Biffi (2017)
10.1007/s11910-017-0783-5
Management of Spontaneous Intracerebral Hemorrhage
R. Veltkamp (2017)
10.1212/WNL.0000000000004235
Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation
E. Korompoki (2017)
10.1212/WNL.0000000000004174
Severity assessment in maximally treated ICH patients
J. Sembill (2017)
10.1136/bmj.j510
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
P. Nielsen (2017)
10.1016/j.ejim.2017.03.012
Oral anticoagulant therapy for older patients with atrial fibrillation: a review of current evidence.
M. Bo (2017)
10.1212/WNL.0000000000004704
Brain microbleeds, anticoagulation, and hemorrhage risk
A. Charidimou (2017)
10.1056/NEJMoa1802686
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
R. Hart (2018)
10.1161/STROKEAHA.118.021799
Cardioembolic Stroke Risk and Recovery After Anticoagulation-Related Intracerebral Hemorrhage
Meredith P Murphy (2018)
10.5853/jos.2018.02537
Percutaneous Left Atrial Appendage Occlusion for the Prevention of Stroke in Patients with Atrial Fibrillation: Review and Critical Appraisal
P. Schellinger (2018)
10.1007/s00415-018-9009-2
Initiating anticoagulant therapy after ICH is associated with patient characteristics and treatment recommendations
J. Sembill (2018)
10.1111/jth.14131
A systematic review and Bayesian network meta‐analysis of risk of intracranial hemorrhage with direct oral anticoagulants
Z. Wolfe (2018)
10.1136/bmjopen-2017-019672
Resuming anticoagulants after anticoagulation-associated intracranial haemorrhage: systematic review and meta-analysis
Zien Zhou (2018)
10.1093/eurheartj/ehy136
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
J. Steffel (2018)
10.1161/CIRCULATIONAHA.117.031658
Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study
T. Chao (2018)
10.1161/STROKEAHA.117.017952
Stroke Prevention in the Very Elderly.
R. Lindley (2018)
10.1016/j.jjcc.2018.01.015
Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: A systematic review and meta-analysis.
I. Kim (2018)
10.1161/JAHA.117.007633
Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
B. Steinberg (2018)
10.1161/STR.0000000000000158
2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
W. Powers (2018)
10.1016/j.chest.2018.07.040
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report
G. Lip (2018)
10.1093/ageing/afx103
Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis
Ying Bai (2018)
10.1002/phar.2158
Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010–2017
Junya Zhu (2018)
10.1177/1747493019870651
Optimal delay time to initiate anticoagulation after ischemic stroke in atrial fibrillation (START): Methodology of a pragmatic, response-adaptive, prospective randomized clinical trial
Benjamin T King (2019)
10.1016/j.jstrokecerebrovasdis.2019.07.008
Resumption of Direct Oral Anticoagulants in Patients with Acute Spontaneous Intracerebral Hemorrhage.
Y. Kato (2019)
10.1161/STROKEAHA.118.022856
Anticoagulation After Stroke in Patients With Atrial Fibrillation.
R. Altavilla (2019)
10.1056/NEJMoa1813959
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
H. Diener (2019)
10.1016/j.archger.2018.12.013
Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis.
D. Caldeira (2019)
10.3390/jcm8040554
Effectiveness and Safety of Direct Oral Anticoagulants versus Vitamin K Antagonists for People Aged 75 Years and over with Atrial Fibrillation: A Systematic Review and Meta-Analyses of Observational Studies
A. Mitchell (2019)
10.1177/1747493019828555
Management of oral anticoagulation after intracerebral hemorrhage
J. Kuramatsu (2019)
10.1016/S0140-6736(19)30840-2
Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial
Rustam MS PAG CLM JM WN GD J DE N DJ PM Colin Daniel Fran Al-Shahi Salman Dennis Sandercock Sudlow Wardlaw W (2019)



Semantic Scholar Logo Some data provided by SemanticScholar